Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Beyond Biological Chelation: Coordination of f-Block Elements by Polyhydroxamate Ligands.

Sockwell AK, Wetzler M.

Chemistry. 2019 Feb 18;25(10):2380-2388. doi: 10.1002/chem.201803176. Epub 2018 Dec 11.

PMID:
30159949
2.

Injuries in the Chinese Arena Football League: American Versus Chinese Players.

Chen T, Wetzler A, Singer S, Feldman M, Rubenstein D, Gillespie G, Chen S, Wetzler M.

Orthop J Sports Med. 2018 Jun 26;6(6):2325967118780040. doi: 10.1177/2325967118780040. eCollection 2018 Jun.

3.
4.

Editorial Commentary: Don't Forgot the Hip in Swimmers and Multisport Athletes.

Wetzler MJ.

Arthroscopy. 2018 May;34(5):1478-1479. doi: 10.1016/j.arthro.2018.01.032.

PMID:
29729757
5.

Intracellular biomass flocculation as a key mechanism of rapid bacterial killing by cationic, amphipathic antimicrobial peptides and peptoids.

Chongsiriwatana NP, Lin JS, Kapoor R, Wetzler M, Rea JAC, Didwania MK, Contag CH, Barron AE.

Sci Rep. 2017 Dec 1;7(1):16718. doi: 10.1038/s41598-017-16180-0.

6.
8.

Related Research and Arthroscopy: Increasing the Breadth of Arthroscopy and Arthroscopy Techniques.

Wetzler MJ, Brand JC, Rossi MJ, Lubowitz JH.

Arthroscopy. 2017 Nov;33(11):1916-1917. doi: 10.1016/j.arthro.2017.08.280.

PMID:
29102005
9.

Editorial Commentary: Belt and Suspenders-Linked Single-Row Rotator Cuff Repair.

Wetzler MJ.

Arthroscopy. 2017 May;33(5):945. doi: 10.1016/j.arthro.2016.12.016.

PMID:
28476370
10.

Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia.

Vachhani P, Shin S, Baron J, Thompson JE, Wetzler M, Griffiths EA, Ontiveros EP, Spangenthal EJ, Wang ES.

Leuk Res Rep. 2017 Apr 14;7:36-39. doi: 10.1016/j.lrr.2017.04.001. eCollection 2017.

11.

Research Pearls: The Significance of Statistics and Perils of Pooling. Part 2: Predictive Modeling.

Hohmann E, Wetzler MJ, D'Agostino RB Jr.

Arthroscopy. 2017 Jul;33(7):1423-1432. doi: 10.1016/j.arthro.2017.01.054. Epub 2017 Apr 28.

PMID:
28457678
12.
13.

Editorial Commentary: Google It!-Reliability of Medical Information Found on the Internet.

Wetzler MJ.

Arthroscopy. 2016 Oct;32(10):2090-2091. doi: 10.1016/j.arthro.2016.06.039.

PMID:
27697186
14.

Editorial Commentary: Pitching Should Come With a Warning Label.

Wetzler MJ.

Arthroscopy. 2016 Aug;32(8):1569-70. doi: 10.1016/j.arthro.2016.06.001.

PMID:
27495862
15.

Adjustment to Acute Leukemia: The Impact of Social Support and Marital Satisfaction on Distress and Quality of Life Among Newly Diagnosed Patients and Their Caregivers.

Pailler ME, Johnson TM, Kuszczak S, Attwood KM, Zevon MA, Griffiths E, Thompson J, Wang ES, Wetzler M.

J Clin Psychol Med Settings. 2016 Sep;23(3):298-309. doi: 10.1007/s10880-016-9459-6.

PMID:
27424023
16.

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression.

Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, Jordan CT, Becker MW.

Blood. 2016 Sep 29;128(13):1671-8. doi: 10.1182/blood-2016-02-695312. Epub 2016 Jul 15.

17.

Editorial Commentary: Many Ways to Skin a Cat.

Wetzler MJ.

Arthroscopy. 2016 Apr;32(4):586. doi: 10.1016/j.arthro.2016.02.002.

PMID:
27039681
18.

Editorial Commentary: Think Twice, Cut Once.

Wetzler MJ.

Arthroscopy. 2016 Mar;32(3):473-4. doi: 10.1016/j.arthro.2015.12.040.

PMID:
26945954
19.

Editorial Commentary: Risks Versus Benefits.

Wetzler MJ.

Arthroscopy. 2016 Mar;32(3):458. doi: 10.1016/j.arthro.2015.12.041.

PMID:
26945952
20.

A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.

Griffiths EA, Brady WE, Tan W, Vigil CE, Thompson JE, Ford LA, Dickey NM, L Bashaw H, Sperrazza J, Wetzler M, Wang ES.

Leuk Res. 2016 Apr;43:44-8. doi: 10.1016/j.leukres.2016.02.003. Epub 2016 Feb 16.

PMID:
26943703
21.

Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.

DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W.

Leuk Lymphoma. 2016 Oct;57(10):2298-306. doi: 10.3109/10428194.2016.1144881. Epub 2016 Feb 18.

22.

Editorial Commentary: Reinventing the Anterior Cruciate Ligament.

Wetzler MJ.

Arthroscopy. 2016 Feb;32(2):330-1. doi: 10.1016/j.arthro.2015.12.010.

PMID:
26814394
23.

Clinical updates in adult acute lymphoblastic leukemia.

Al Ustwani O, Gupta N, Bakhribah H, Griffiths E, Wang E, Wetzler M.

Crit Rev Oncol Hematol. 2016 Mar;99:189-99. doi: 10.1016/j.critrevonc.2015.12.007. Epub 2015 Dec 19. Review.

PMID:
26777876
24.

Discontinuation of Systematic Surveillance and Contact Precautions for Vancomycin-Resistant Enterococcus (VRE) and Its Impact on the Incidence of VRE faecium Bacteremia in Patients with Hematologic Malignancies.

Almyroudis NG, Osawa R, Samonis G, Wetzler M, Wang ES, McCarthy PL, Segal BH.

Infect Control Hosp Epidemiol. 2016 Apr;37(4):398-403. doi: 10.1017/ice.2015.310. Epub 2016 Jan 11.

PMID:
26750087
25.

Editorial Commentary: Doc, Can You Inject Stem Cells in My Knee?

Wetzler MJ.

Arthroscopy. 2016 Jan;32(1):110. doi: 10.1016/j.arthro.2015.11.013.

PMID:
26743414
26.

Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.

Torka P, Al Ustwani O, Wetzler M, Wang ES, Griffiths EA.

Blood Rev. 2016 May;30(3):201-11. doi: 10.1016/j.blre.2015.11.004. Epub 2015 Dec 3. Review.

PMID:
26709030
27.

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.

Wetzler M, Kantarjian HM, Nicolini FE, Lipton JH, Akard L, Baccarani M, Khoury HJ, Li E, Munteanu M, Cortes J.

Blood Cancer J. 2015 Dec 11;5:e376. doi: 10.1038/bcj.2015.104. No abstract available.

28.

Polo-like kinase inhibitors in hematologic malignancies.

Talati C, Griffiths EA, Wetzler M, Wang ES.

Crit Rev Oncol Hematol. 2016 Feb;98:200-10. doi: 10.1016/j.critrevonc.2015.10.013. Epub 2015 Nov 4. Review.

PMID:
26597019
29.

Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.

Akard L, Kantarjian HM, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Jean Khoury H, Kurtin S, Li E, Munteanu M, Cortes J.

Leuk Lymphoma. 2016;57(3):654-65. doi: 10.3109/10428194.2015.1071486. Epub 2015 Oct 5.

30.

Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.

Muppidi MR, Portwood S, Griffiths EA, Thompson JE, Ford LA, Freyer CW, Wetzler M, Wang ES.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S73-9. doi: 10.1016/j.clml.2015.02.033.

PMID:
26297284
31.

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.

Sanford D, Lo-Coco F, Sanz MA, Di Bona E, Coutre S, Altman JK, Wetzler M, Allen SL, Ravandi F, Kantarjian H, Cortes JE.

Br J Haematol. 2015 Nov;171(4):471-7. doi: 10.1111/bjh.13607. Epub 2015 Jul 24.

32.

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL.

Nature. 2015 Jul 9;523(7559):183-188. doi: 10.1038/nature14610. Epub 2015 Jul 1.

33.

Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.

Rogala B, Freyer CW, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M.

Expert Opin Biol Ther. 2015 Jun;15(6):895-908. doi: 10.1517/14712598.2015.1041912. Review.

34.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA.

J Natl Compr Canc Netw. 2015 Apr;13(4):424-34. Review.

PMID:
25870379
35.

Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.

Gupta N, Miller A, Gandhi S, Ford LA, Vigil CE, Griffiths EA, Thompson JE, Wetzler M, Wang ES.

Am J Hematol. 2015 Jul;90(7):639-46. doi: 10.1002/ajh.24016.

36.

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.

Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B.

J Clin Oncol. 2015 Apr 10;33(11):1252-7. doi: 10.1200/JCO.2014.57.0952. Epub 2015 Mar 2.

PMID:
25732165
37.

An oncologist's perspective on metformin use and acute lymphoblastic leukemia outcomes.

Wang ES, Wetzler M.

J Pharm Pract. 2015 Feb;28(1):46-7. doi: 10.1177/0897190014557627. No abstract available.

PMID:
25715082
38.

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.

Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA.

Am J Hematol. 2015 May;90(5):E77-9. doi: 10.1002/ajh.23965. Epub 2015 Feb 27.

39.

Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M.

Blood Rev. 2015 Jul;29(4):243-9. doi: 10.1016/j.blre.2015.01.001. Epub 2015 Jan 10. Review.

40.

Acceptability, feasibility, and efficacy of a supportive group intervention for caregivers of newly diagnosed leukemia patients.

Pailler ME, Johnson TM, Zevon MA, Kuszczak S, Griffiths E, Thompson J, Wang ES, Wetzler M.

J Psychosoc Oncol. 2015;33(2):163-77. doi: 10.1080/07347332.2014.992086.

PMID:
25587747
41.

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.

Cortes JE, Kantarjian HM, Rea D, Wetzler M, Lipton JH, Akard L, Khoury HJ, Michallet M, Guerci-Bresler A, Chuah C, Hellmann A, Digumarti R, Parikh PM, Legros L, Warzocha K, Baccarani M, Li E, Munteanu M, Nicolini FE.

Cancer. 2015 May 15;121(10):1637-44. doi: 10.1002/cncr.29240. Epub 2015 Jan 13.

42.

How we will treat chronic myeloid leukemia in 2016.

Talati C, Ontiveros EP, Griffiths EA, Wang ES, Wetzler M.

Blood Rev. 2015 Mar;29(2):137-42. doi: 10.1016/j.blre.2014.12.003. Epub 2014 Dec 17. Review.

43.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL.

Blood. 2015 Feb 26;125(9):1367-76. doi: 10.1182/blood-2014-11-610543. Epub 2014 Dec 30.

44.

Expression and prognostic impact of lncRNAs in acute myeloid leukemia.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18679-84. doi: 10.1073/pnas.1422050112. Epub 2014 Dec 15.

45.

Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts.

Griffiths EA, Golding MC, Srivastava P, Povinelli BJ, James SR, Ford LA, Wetzler M, Wang ES, Nemeth MJ.

Haematologica. 2015 Feb;100(2):e49-52. doi: 10.3324/haematol.2014.113118. Epub 2014 Nov 7. No abstract available.

46.

Deletion and deletion/insertion mutations in the juxtamembrane domain of the FLT3 gene in adult acute myeloid leukemia.

Deeb KK, Smonskey MT, DeFedericis H, Deeb G, Sait SN, Wetzler M, Wang ES, Starostik P.

Leuk Res Rep. 2014 Oct 16;3(2):86-9. doi: 10.1016/j.lrr.2013.09.003. eCollection 2014.

47.

Chronic myelogenous leukemia, version 1.2015.

O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H.

J Natl Compr Canc Netw. 2014 Nov;12(11):1590-610.

PMID:
25361806
48.

Omacetaxine mepesuccinate in chronic myeloid leukemia.

Al Ustwani O, Griffiths EA, Wang ES, Wetzler M.

Expert Opin Pharmacother. 2014 Nov;15(16):2397-405. doi: 10.1517/14656566.2014.964642. Review.

PMID:
25301179
49.

Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?

Freyer CW, Gupta N, Wetzler M, Wang ES.

Am J Hematol. 2015 Jan;90(1):62-72. doi: 10.1002/ajh.23862. Epub 2014 Oct 25. Review.

50.

High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure.

Smith MB, Griffiths EA, Thompson JE, Wang ES, Wetzler M, Freyer CW.

Leuk Res Rep. 2014 Jul 30;3(2):62-6. doi: 10.1016/j.lrr.2014.07.001. eCollection 2014.

Supplemental Content

Loading ...
Support Center